Zobrazeno 1 - 10
of 104
pro vyhledávání: '"TAKASHI TAKESHITA"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Oral mucositis (OM) is a common adverse effect of docetaxel-containing treatment. This study aimed to assess whether dexamethasone (DEX) dose-dependently attenuates docetaxel-induced OM and dysgeusia. We retrospectively analyzed medical reco
Externí odkaz:
https://doaj.org/article/a917be787d4d4331a5e29d7e3f6f70d1
Autor:
Yoshitaka Saito, Ryota Kanno, Yoh Takekuma, Takashi Takeshita, Tomohiro Oshino, Mitsuru Sugawara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast ca
Externí odkaz:
https://doaj.org/article/881e8e8c97154e808f55be54608079a7
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Oral mucositis (OM) is one of the most common complications associated with chemotherapy. Here, we evaluated whether systemic dexamethasone (DEX) dosage in prophylactic antiemetics affected the incidence of OM in anthracycline-containing reg
Externí odkaz:
https://doaj.org/article/1253602ab3e341cd997c16c0e0737819
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthra
Externí odkaz:
https://doaj.org/article/d243387fb18d4255bb27707e93a9f380
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1277-1282 (2021)
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postmen
Externí odkaz:
https://doaj.org/article/c69db1284bf4437c997da1f7cd502bb9
Autor:
Takashi Takeshita, Yoshihisa Tokumaru, Masanori Oshi, Rongrong Wu, Ankit Patel, Wanqing Tian, Yutaka Hatanaka, Kanako C. Hatanaka, Li Yan, Kazuaki Takabe
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeEstrogen signals play an important role in the phenotype of estrogen receptor-positive breast cancer. However, comprehensive analyses of the effect of responsiveness to estrogen signals on the tumor microenvironment and survival in large cohor
Externí odkaz:
https://doaj.org/article/8b934e1c74774d65a32e5dc54525bad6
Autor:
Kanako Hagio, Toraji Amano, Hideyuki Hayashi, Takashi Takeshita, Tomohiro Oshino, Junko Kikuchi, Yoshihito Ohhara, Ichiro Yabe, Ichiro Kinoshita, Hiroshi Nishihara, Hiroko Yamashita
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Clinical targeted sequencing allows for the selection of patients expected to have a better treatment response, and reveals mechanisms of resistance to molecular targeted therapies based on actionable gene mutations. We underwent comprehensi
Externí odkaz:
https://doaj.org/article/bcd6587139f6496c8776ae366ad162a1
Autor:
Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Aiko Sueta, Keiichi Murakami, Hirotaka Iwase
Publikováno v:
Molecular Cancer, Vol 17, Iss 1, Pp 1-6 (2018)
Abstract The somatic activation of PI3K/AKT pathway mutations, PIK3CA and AKT1, and ESR1 mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive procedure to quickly assess and monitor disease progression or therapeutic effect in
Externí odkaz:
https://doaj.org/article/8051e735bd994470b2803d53881588e8
Autor:
Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Aiko Sueta, Mai Tomiguchi, Keiichi Murakami, Yoko Omoto, Hirotaka Iwase
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background ESR1 mutations have attracted attention as a potentially important marker and treatment target in endocrine therapy-resistant breast cancer patients. The E380Q mutation, which is one of the ESR1 mutations, is associated with estra
Externí odkaz:
https://doaj.org/article/580f7920044e4ef88faff899288a3722
Autor:
Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Aiko Sueta, Keiichi Murakami, Yoko Omoto, Hirotaka Iwase
Publikováno v:
Translational Oncology, Vol 10, Iss 5, Pp 766-771 (2017)
BACKGROUND: ESR1 mutation in circulating cell-free DNA (cfDNA) is emerging as a noninvasive biomarker of acquired resistance to endocrine therapy, but there is a paucity of data comparing the status of ESR1 gene in cfDNA with that in its correspondin
Externí odkaz:
https://doaj.org/article/02056249fdb041ca9df4e5f943f41eb6